Page 113 - 2021_06-Haematologica-web

Impact of translocations in mutated IGHV CLL at diagnosis
phocytic leukemia identifies karyotype aberrations and TP53 disruption as predic- tors of outcome and chemorefractoriness. Oncotarget. 2017;8(17):28008-28020.
12. Rigolin GM, Cavallari M, Quaglia FM, et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood. 2017;129(26):3495-3498.
13. Le Bris Y, Struski S, Guièze R, et al. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational sta- tus in first-line chronic lymphocytic leukemia. Hematol Oncol. 2017;35(4):664- 670.
14. Cavallari M, Cavazzini F, Bardi A, et al. Biological significance and prognostic/pre- dictive impact of complex karyotype in chronic lymphocytic leukemia. Oncotarget. 2018;9(76):34398-34412.
15. Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lym- phocytic leukemia: definitions, associa- tions, and clinical impact. Blood. 2019;133(11):1205-1216.
16. Rigolin GM, del Giudice I, Formigaro L, et al. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: clinical and biologic correlations. Genes Chromosomes Cancer. 2015;54(12):818- 826.
17. Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocyt- ic leukemia. Blood. 2006;107(2):742-751.
18. Van Den Neste E, Robin V, Francart J, et al. Chromosomal translocations independent- ly predict treatment failure, treatment-free survival and overall survival in B-cell chron- ic lymphocytic leukemia patients treated with cladribine. Leukemia. 2007;21(8): 1715-1722.
19. Rigolin GM, Saccenti E, Guardalben E, et al. In chronic lymphocytic leukaemia with complex karyotype, major structural abnor- malities identify a subset of patients with inferior outcome and distinct biological characteristics. Br J Haematol. 2018;181(2): 229-233.
20. Herling CD, Klaumünzer M, Rocha CK, et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016;128(3): 395-404.
21. Decker T, Schneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 recep- tors on B-CLL cells: costimulation with IL- 2 results in a highly immunogenic pheno-
type. Exp Hematol. 2000;28(5):558-568. 22. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood.
2000;95(3):999-1006.
23. Dicker F, Schnittger S, Haferlach T, Kern W,
Schoch C. Immunostimulatory oligonu- cleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood. 2006;108(9):3152-3160.
24. Muthusamy N, Breidenbach H, Andritsos L, et al. Enhanced detection of chromoso- mal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. Cancer Genet. 2011;204 (2):77-83.
25. Put N, Konings P, Rack K, et al. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conven- tional cytogenetics using CpG oligonu- cleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer. 2009;48(10):843- 853.
26.Struski S, Gervais C, Helias C, et al. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia. 2009;23(3): 617-619.
CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutat- ed IGHV status. Br J Haematol. 2016;172 (1):48-55.
32.Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111(2):865-873.
33. Del Giudice I, Mauro FR, De Propris MS, et al. White blood cell count at diagnosis and immunoglobulin variable region gene muta- tions are independent predictors of treat- ment-free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica. 2011;96(4):626-630.
34. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chron- ic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
35. Foa R, Del Giudice I, Guarini A, Rossi D, Gaidano G. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica. 2013;98(5):675- 685.
36. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk dis- ease. J Clin Oncol. 2009;27(35):6012-6018.
37. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lympho- cytic leukemia. J Clin Oncol. 2010;28(29): 4473-4479.
38. Stephens DM, Ruppert AS, Weirda WG, et al. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol. 2015;90(11):967-969.
39. Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lympho- cytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009;114 (5):957-964.
40. Van Dyke DL, Werner L, Rassenti LZ, et al. The Dohner fluorescence in situ hybridiza- tion prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol 2016;173(1):105-113.
41.Yu L, Kim HT, Kasar S, et al. Survival of del17p CLL depends on genomic complex- ity and somatic mutation. Clin Cancer Res 2017;23(3):735-745.
27.
Haferlach C, Jeromin S, Nadarajah N, et al. Cytogenetic and molecular genetic clonal evolution in CLL is associated with an unmutated IGHV status and frequently leads to a combination of loss of 17p and TP53 mutation. Blood. 2016;128(22):3213- 3213.
28. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007;92(9):1242-1245.
29. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
30. Pepper C, Buggins AG, Jones CH, et al. Phenotypic heterogeneity in IGHV-mutat- ed CLL patients has prognostic impact and identifies a subset with increased sensitivi- ty to BTK and PI3Kd inhibition. Leukemia. 2015;29(3):744-747.
31. Baumann T, Delgado J, Santacruz R, et al.
42.
Liu G, Parant JM, Lang G, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet. 2004;36(1):63-68.
haematologica | 2021; 106(6)
1615